AIMSPRO is a subcutaneously delivered peptide/polyclonal "large biologic" technically described as hyperimmune caprine serum raised against an inactivated HIV IIIB viral lysate. AIMSPRO has demonstrated powerful and well-tolerated anti-inflammatory capabilities. AIMSPRO exhibits tri-partite functionality by targeting the HPA axis and other pathways and by regulating several key intracellular protein kinases via a highly coordinated mechanism that gives the drug considerable biodiversity and possible application.
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic unpredictable neurological disease affecting 2.5 million people worldwide. Multiple sclerosis can cause blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, difficulties with memory and concentration, paralysis, stiffness, bladder problems and blindness. Though most people with multiple sclerosis are diagnosed between the ages of 20 and 40, the unpredictable physical and emotional effects are life-long. The progress, severity, and specific symptoms of multiple sclerosis vary greatly from person to person. Because of the complexity of the disease, the cause and pathology of multiple sclerosis are still not known.
DAVAL INTERNATIONAL LIMITED is an emerging life sciences company
focused on the development and delivery of novel and distinctive
treatments for serious unmet medical needs through a combination of
innovation, dedication, entrepreneurship, skilled science and
partnership. From its inception in 2000, the founder and management
team of Daval have had a vision of bringing effective treatments
that noticeably improves the quality of life of patients suffering
from the most serious debilitating neuro-d
|SOURCE Daval International|
Copyright©2010 PR Newswire.
All rights reserved